echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca/Mersk’s Lynparza combined with Roche Avastin is recommended in the UK for the treatment of ovarian cancer

    AstraZeneca/Mersk’s Lynparza combined with Roche Avastin is recommended in the UK for the treatment of ovarian cancer

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompileKe Ke

    Recently, foreign media reported that the National Institute of Health Care Excellence (NICE) recommended AstraZeneca/Mersk’s Lynparza (Olabarib) and Roche’s Avastin (bevacizumab) through the Cancer Drug Fund (CDF).


    This recommendation is based on data from the phase 3 clinical study PAOLA-1.


    In this study, about 48% of patients were newly diagnosed patients with HRD-positive advanced ovarian cancer.


    The British National Health System (NHS) supports the introduction of olaparib combined with bevacizumab therapy, and the organization is providing genomic HRD testing for patients who use the therapy for the first time.


    Olabarib is known as a PARP inhibitor as an inhibitor of poly ADP ribose polymerase (PARP).


    In December 2014, the European Medicines Agency (EMA) and the U.


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.